Protalix BioTherapeutics
PLX
29 hedge funds and large institutions have $12.5M invested in Protalix BioTherapeutics in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
4% more funds holding
Funds holding: 28 → 29 (+1)
0.2% less ownership
Funds ownership: 2.43% → 2.23% (-0.2%)
20% less capital invested
Capital invested by funds: $15.5M → $12.5M (-$3.03M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $12K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$48.6K |
| 2 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$25.2K |
| 3 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$24.9K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$7.48K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$1.3M |
| 2 |
Barclays
London,
United Kingdom
|
-$74.6K |
| 3 |
SIM
Spark Investment Management
New York
|
-$7.55K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$7K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.64K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $1K | – | – | – |
|
|
BC
27
Broadfin Capital
New York
| – | -$1.3M | -202,527 | Closed |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$7K | -1,068 | Closed |
|
PLX Hedge Fund Activity: Q3 2016 in Review
29 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2016, worth a combined $12.5M — down 20% from $15.5M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PLX positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $48.6K. The largest seller was Broadfin Capital, exiting entirely with an estimated $1.3M sold.
- 29 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2016, up from 28 in Q2 2016.
- Funds reported $12.5M of Protalix BioTherapeutics stock for Q3 2016, down 20% quarter-over-quarter.
- 4 funds opened new Protalix BioTherapeutics positions in Q3 2016 and 3 closed out, a net change of +1 holder.
- The largest Protalix BioTherapeutics buyer in Q3 2016 was Renaissance Technologies, an estimated $48.6K added.
- The largest Protalix BioTherapeutics seller in Q3 2016 was Broadfin Capital, an estimated $1.3M sold.
Based on aggregated 13F filings for Q3 2016.